Titre : Tumeurs sous-tentorielles

Tumeurs sous-tentorielles : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs sous-tentorielles : Questions médicales les plus fréquentes", "headline": "Tumeurs sous-tentorielles : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs sous-tentorielles : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-15", "dateModified": "2024-11-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs sous-tentorielles" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs du cerveau", "url": "https://recherchemedicale.com/mesh/D001932", "about": { "@type": "MedicalCondition", "name": "Tumeurs du cerveau", "code": { "@type": "MedicalCode", "code": "D001932", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.551.240.250" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs du tronc cérébral", "alternateName": "Brain Stem Neoplasms", "url": "https://recherchemedicale.com/mesh/D020295", "about": { "@type": "MedicalCondition", "name": "Tumeurs du tronc cérébral", "code": { "@type": "MedicalCode", "code": "D020295", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.551.240.250.400.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gliome infiltrant du tronc cérébral", "alternateName": "Diffuse Intrinsic Pontine Glioma", "url": "https://recherchemedicale.com/mesh/D000080443", "about": { "@type": "MedicalCondition", "name": "Gliome infiltrant du tronc cérébral", "code": { "@type": "MedicalCode", "code": "D000080443", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.551.240.250.400.200.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Tumeurs du cervelet", "alternateName": "Cerebellar Neoplasms", "url": "https://recherchemedicale.com/mesh/D002528", "about": { "@type": "MedicalCondition", "name": "Tumeurs du cervelet", "code": { "@type": "MedicalCode", "code": "D002528", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.551.240.250.400.300" } } } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs sous-tentorielles", "alternateName": "Infratentorial Neoplasms", "code": { "@type": "MedicalCode", "code": "D015192", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Robert F Spetzler", "url": "https://recherchemedicale.com/author/Robert%20F%20Spetzler", "affiliation": { "@type": "Organization", "name": "Division of Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, USA." } }, { "@type": "Person", "name": "Roberto Rodriguez Rubio", "url": "https://recherchemedicale.com/author/Roberto%20Rodriguez%20Rubio", "affiliation": { "@type": "Organization", "name": "Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States. Electronic address: luis.rodriguezrubio@ucsf.edu." } }, { "@type": "Person", "name": "L Dade Lunsford", "url": "https://recherchemedicale.com/author/L%20Dade%20Lunsford", "affiliation": { "@type": "Organization", "name": "Department of Neurological Surgery, UPMC, PA, Pittsburgh, USA." } }, { "@type": "Person", "name": "Michael G Brandel", "url": "https://recherchemedicale.com/author/Michael%20G%20Brandel", "affiliation": { "@type": "Organization", "name": "Department of Neurosurgery, University of California, La Jolla, San Diego, CA, USA." } }, { "@type": "Person", "name": "Manish Beniwal", "url": "https://recherchemedicale.com/author/Manish%20Beniwal", "affiliation": { "@type": "Organization", "name": "Department of Neurosurgery, NIMHANS, Bangalore, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.", "datePublished": "2024-03-01", "url": "https://recherchemedicale.com/article/38426696", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5858/arpa.2023-0363-OA" } }, { "@type": "ScholarlyArticle", "name": "Case report: Treatment of intraductal papillary mucinous neoplasms located in middle-segment pancreas with end-to-end anastomosis reconstruction after laparoscopic central pancreatectomy surgery through a pigtail-tube-stent placement of the pancreatic duct.", "datePublished": "2022-09-01", "url": "https://recherchemedicale.com/article/36117840", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fsurg.2022.937682" } }, { "@type": "ScholarlyArticle", "name": "Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group.", "datePublished": "2022-02-04", "url": "https://recherchemedicale.com/article/35119651", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12185-022-03290-3" } }, { "@type": "ScholarlyArticle", "name": "Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).", "datePublished": "2022-03-17", "url": "https://recherchemedicale.com/article/35326695", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14061544" } }, { "@type": "ScholarlyArticle", "name": "Comparison of the procedure time differences between hybrid endoscopic submucosal dissection and conventional endoscopic submucosal dissection in patients with early gastric neoplasms: a study protocol for a multi-center randomized controlled trial (Hybrid-G trial).", "datePublished": "2022-02-21", "url": "https://recherchemedicale.com/article/35189939", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-022-06099-x" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Recherchemedicale.com", "item": "https://recherchemedicale.com" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://recherchemedicale.com/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs du système nerveux", "item": "https://recherchemedicale.com/mesh/D009423" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs du système nerveux central", "item": "https://recherchemedicale.com/mesh/D016543" }, { "@type": "ListItem", "position": 5, "name": "Tumeurs du cerveau", "item": "https://recherchemedicale.com/mesh/D001932" }, { "@type": "ListItem", "position": 6, "name": "Tumeurs sous-tentorielles", "item": "https://recherchemedicale.com/mesh/D015192" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs sous-tentorielles - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs sous-tentorielles", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-01-23", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs sous-tentorielles", "description": "Comment diagnostique-t-on une tumeur sous-tentorielle ?\nQuels tests sont utilisés pour confirmer une tumeur ?\nQuels symptômes initiaux peuvent indiquer une tumeur ?\nQuelle est l'importance de l'évaluation neurologique ?\nLes examens sanguins sont-ils utiles pour le diagnostic ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs sous-tentorielles", "description": "Quels sont les symptômes courants des tumeurs sous-tentorielles ?\nComment les tumeurs affectent-elles l'équilibre ?\nLes nausées sont-elles fréquentes ?\nPeut-on avoir des troubles de la parole ?\nLes convulsions sont-elles un symptôme possible ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs sous-tentorielles", "description": "Peut-on prévenir les tumeurs sous-tentorielles ?\nQuels facteurs de risque sont connus ?\nL'exposition à des radiations augmente-t-elle le risque ?\nLes infections virales sont-elles un facteur de risque ?\nLe mode de vie influence-t-il le risque ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs sous-tentorielles", "description": "Quels traitements sont disponibles pour ces tumeurs ?\nQuand la chirurgie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nQuels sont les effets secondaires des traitements ?\nLa chimiothérapie est-elle utilisée pour ces tumeurs ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs sous-tentorielles", "description": "Quelles complications peuvent survenir ?\nLes tumeurs peuvent-elles causer des dommages permanents ?\nComment les complications sont-elles gérées ?\nLes complications affectent-elles la qualité de vie ?\nLes récidives sont-elles possibles après traitement ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs sous-tentorielles", "description": "Quels sont les principaux facteurs de risque ?\nLes tumeurs sous-tentorielles sont-elles héréditaires ?\nL'âge influence-t-il le risque de tumeurs ?\nLes troubles immunitaires augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque ?", "url": "https://recherchemedicale.com/mesh/D015192?page=348#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une tumeur sous-tentorielle ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par IRM cérébrale et évaluation neurologique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer une tumeur ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des tests d'imagerie avancés comme la TEP peuvent être utilisés." } }, { "@type": "Question", "name": "Quels symptômes initiaux peuvent indiquer une tumeur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des maux de tête, des nausées et des troubles de l'équilibre peuvent survenir." } }, { "@type": "Question", "name": "Quelle est l'importance de l'évaluation neurologique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à déterminer l'impact de la tumeur sur les fonctions cérébrales." } }, { "@type": "Question", "name": "Les examens sanguins sont-ils utiles pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent aider à exclure d'autres conditions, mais ne diagnostiquent pas directement." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des tumeurs sous-tentorielles ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Maux de tête, vertiges, troubles de la coordination et vision floue." } }, { "@type": "Question", "name": "Comment les tumeurs affectent-elles l'équilibre ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent perturber le cervelet, responsable de la coordination et de l'équilibre." } }, { "@type": "Question", "name": "Les nausées sont-elles fréquentes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent causées par une pression intracrânienne accrue." } }, { "@type": "Question", "name": "Peut-on avoir des troubles de la parole ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, si la tumeur affecte les zones du cerveau liées à la parole." } }, { "@type": "Question", "name": "Les convulsions sont-elles un symptôme possible ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent survenir en raison de l'irritation cérébrale causée par la tumeur." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs sous-tentorielles ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique pour ces tumeurs." } }, { "@type": "Question", "name": "Quels facteurs de risque sont connus ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines conditions génétiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'exposition à des radiations augmente-t-elle le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des radiations ionisantes est un facteur de risque reconnu." } }, { "@type": "Question", "name": "Les infections virales sont-elles un facteur de risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus Epstein-Barr, peuvent être liées." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de plusieurs types de cancers, mais pas spécifiquement." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour ces tumeurs ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Chirurgie, radiothérapie et chimiothérapie sont les options principales." } }, { "@type": "Question", "name": "Quand la chirurgie est-elle recommandée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent recommandée si la tumeur est accessible et provoque des symptômes." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut réduire la taille de la tumeur et soulager les symptômes." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, nausées et troubles neurologiques peuvent survenir après traitement." } }, { "@type": "Question", "name": "La chimiothérapie est-elle utilisée pour ces tumeurs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elle est parfois utilisée, surtout pour les tumeurs malignes ou récurrentes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des déficits neurologiques, des convulsions et des infections." } }, { "@type": "Question", "name": "Les tumeurs peuvent-elles causer des dommages permanents ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dommages neurologiques permanents peuvent résulter d'une pression prolongée." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont gérées par des traitements symptomatiques et des interventions chirurgicales." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement réduire la qualité de vie des patients." } }, { "@type": "Question", "name": "Les récidives sont-elles possibles après traitement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines tumeurs peuvent récidiver, nécessitant un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Antécédents familiaux, exposition aux radiations et certaines maladies génétiques." } }, { "@type": "Question", "name": "Les tumeurs sous-tentorielles sont-elles héréditaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Certaines tumeurs peuvent avoir une composante héréditaire, mais ce n'est pas courant." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de tumeurs ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines tumeurs sont plus fréquentes chez les enfants et les jeunes adultes." } }, { "@type": "Question", "name": "Les troubles immunitaires augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées peuvent avoir un risque accru de néoplasmes." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines tumeurs peuvent être plus fréquentes chez un sexe, mais cela varie selon le type." } } ] } ] }

Sources (3480 au total)

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.

BCR::ABL-negative myeloproliferative neoplasm (MPN) has a prolonged clinical course, and some cases eventually undergo transformation to blast phase; its pathogenesis remains to be elucidated.... To evaluate the clinicopathologic characteristics of MPN in blast phase.... The study aimed to retrospectively analyze the clinical and laboratory data of 24 cases.... Median latency to blast phase was 48 months (range, 7-384 months). Complex karyotypes were seen in 12 of the 24 cases (50%). Overall, 16 cases (66.7%) exhibited high allele burdens of MPN driver mutat... MPN-blast phase resembles acute myeloid leukemia, myelodysplasia-related, in cytogenetic pattern, mutation profile, and clinical outcome. Two patterns of clonal evolution are inferred by dynamic analy...

Case report: Treatment of intraductal papillary mucinous neoplasms located in middle-segment pancreas with end-to-end anastomosis reconstruction after laparoscopic central pancreatectomy surgery through a pigtail-tube-stent placement of the pancreatic duct.

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is one type of pancreatic cystic neoplasm. IPMNs can be classified into three types: main duct-IPMN (MD-IPMN), branch duct-IPMN (BD-IPMN)...

Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group.

Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms' tumor 1 (WT1) mRNA express... We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo.... The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (p < 0.01) and... The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA....

Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).

Purpose: To assess humoral responses longitudinally and cellular immunogenicity following SARS-CoV-2-vaccination in patients with hematologic and oncologic malignancies receiving checkpoint-inhibitors...

Comparison of the procedure time differences between hybrid endoscopic submucosal dissection and conventional endoscopic submucosal dissection in patients with early gastric neoplasms: a study protocol for a multi-center randomized controlled trial (Hybrid-G trial).

Endoscopic submucosal dissection (ESD) is widely accepted as a local treatment for gastrointestinal tract tumors. As a simplified endoscopic procedure, hybrid ESD (H-ESD) has been performed for colore... This is an investigator-initiated, multi-center, prospective, randomized, open-label, parallel-group trial to be conducted beginning in August 2020 at nine institutions in Japan. We will determine if ... This trial will provide high-quality data on the benefits and risks of H-ESD for EGN patients. The results of this study could lead to improved outcomes in patients with EGN undergoing ESD. The result... UMIN-CTR UMIN000041244 . Registered on July 29, 2020....

Can the analysis of chromatin texture and nuclear fractal dimensions serve as effective means to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features from other malignancies with follicular pattern in the thyroid?: a study.

Thyroid carcinoma ranks as the 9th most prevalent global cancer, accounting for 586,202 cases and 43,636 deaths in 2020. Computerized image analysis, utilizing artificial intelligence algorithms, emer... This study aims to assess and compare chromatin textural characteristics and nuclear dimensions in follicular neoplasms through gray-level co-occurrence matrix (GLCM), fractal, and morphometric analys... A retrospective cross-sectional study involving 115 thyroid malignancies, specifically 49 papillary thyroid carcinomas with follicular morphology, was conducted from July 2021 to July 2023. Ethical ap... A statistically significant difference was observed in contrast (2.426 (1.774-3.412) vs 2.664 (1.963-3.610),... Computerized image analysis, though promising in subtype discrimination, requires further refinement and integration with traditional diagnostic parameters. The study suggests potential applications i...

Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers.

Intraductal papillary mucinous neoplasms (IPMNs) are premalignant cystic neoplasms of the pancreas (CNPs), which can progress to invasive IPMN and pancreatic cancer. The available literature has shown... This study aims to characterize the oncologic outcomes and metastatic progression pattern after the resection of non-metastatic invasive IPMN.... Data were obtained from 24 clinical cancer registries participating in the German Cancer Registry Group of the Society of German Tumor Centers (ADT). Patients with invasive IPMN (... Invasive IPMN was significantly smaller in size (... Invasive IPMN is a rare pancreatic entity with increasing incidence in Germany. It is associated with favorable histopathological features at the time of resection and longer OS and DFS compared to PD...

Organ preserving pancreatic resections offer better long-term conservation of pancreatic function at the expense of high perioperative major morbidity: a fair trade-off for benign or low malignant potential pancreatic neoplasms-a single-center experience.

Standard pancreatic resections (SPRs) might have long-term deleterious effects on pancreatic function, without added oncological advantage in low malignant potential (LMP) or benign neoplasms. This st... Post hoc analysis of patients undergoing OPPAR or SPR for benign or LMP pancreatic tumors from January 2011 to January 2020 at Tata Memorial Hospital, Mumbai.... Thirty-six and 114 patients were identified in OPPAR and SPR groups respectively. The overall morbidity (58.3% vs 43.9%, p-0.129) was comparable. Major morbidity (41.7% vs 21.9%, p-0.020), post-operat... OPPAR is associated with high post-operative major morbidity and pancreatic fistula rate but offers long-term benefit due to better preservation of pancreatic function than SPR. The incidence of exocr...

Safety and efficacy study of laparoscopic or robotic radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasms evaluating survival (SOLUTION): a multi-centre, open-label, single-arm, phase II trial protocol.

The Laparoscopic Approach to Cervical Cancer trial and Surveillance, Epidemiology, and End Results program database study demonstrated that minimally invasive radical hysterectomy was inferior to abdo... This trial is a prospective, multi-centre, open-label, single-arm, non-inferiority phase II study. The nine organisations will participate in this trial after the approval of the institutional review ... We expect intracorporeal colpotomy using an endoscopic stapler may prevent tumour spillage during MIS for stage IB1 cervical cancer, showing a comparable prognosis with abdominal radical surgery.... ClinicalTrials.gov ; NCT04370496 ; registration date, May 2020....

Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography's standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.

Identifying malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) remains challenging, but the standardized uptake value (SUV) obtained from... We assessed 58 patients with confirmed BD-IPMN undergoing surgery between 2008 and 2022. Receiver operating characteristic curves were plotted using the tumor-to-blood pool ratio (TBR) of FDG-PET/CT i... In the cohort of 58 cases, there were 39 females, and the median age was 71 years. The median TBR value was 1.45 (range, 0.35-25.44). The TBRs exhibited a significant correlation with each histopathol... TBR might have the potential to serve as a valuable parameter for indicating malignant transformation in pancreatic BD-IPMNs....